Novartis Selects J&J's Costa To Head U.S. Drug Business
Executive Summary
Johnson & Johnson Exec VP-Global Franchise Development Paulo Costa has been named president and CEO of Novartis' pharma business in the U.S.
You may also be interested in...
Novartis, AstraZeneca Cede Seed Business: Two Pharma Pure Plays Created
The Novartis/AstraZeneca agribusiness spin-off reflects the "limited" synergies between the agricultural and pharmaceutical businesses, the two companies maintained.
Novartis, AstraZeneca Cede Seed Business: Two Pharma Pure Plays Created
The Novartis/AstraZeneca agribusiness spin-off reflects the "limited" synergies between the agricultural and pharmaceutical businesses, the two companies maintained.
Novartis To File Zelmac For Irritable Bowel Syndrome In 1999-2000
Novartis' irritable bowel syndrome therapy Zelmac (tegaserode) is one of four new therapies the firm plans to file with FDA in 1999-2000, Novartis Chairman designate and CEO Daniel Vasella indicated at a review of the company's 1998 financial results in London March 16.